by Chris Dokomajilar | May 15, 2023 | Analysis, Partnership Deals
First quarter 2023 R&D partnerships for biopharma therapeutics and platforms followed very similar trends from 2022 with continued declines in venture investment and dealmaking. One area that did pick up slightly in the total Q1 2023 numbers was biopharma M&A,...
by Chris Dokomajilar | May 3, 2023 | Analysis, Partnership Deals
There has been a significant decrease in R&D licensing and partnership activity from the previous quarter, dropping from $55.9 billion to $35.4 billion in Q1 2023. Q1 2023 R&D Partnerships Set to Drive Growth $35.4 billion in total R&D partnership deal...
by Chris Dokomajilar | Apr 19, 2023 | Analysis, Funding, M&A, Partnership Deals
R&D Partnerships, M&A, Ventures, and IPOs by TA – Neurology The biotech industry is facing a critical moment as it enters 2023. The previous year was challenging for the sector, as initial public offerings decreased, and a biotech stock index declined by...
by Chris Dokomajilar | Apr 3, 2023 | Analysis, Funding, M&A, Partnership Deals
Deal Flow in 2022 Returned to pre-2019 Levels Lower Deal Dollars Across All Healthcare and Life Sciences Licensing Terms are Shifting to More in Milestones Large Cap Biopharma In-Licensing and Buying in 2022 Big...
by Chris Dokomajilar | Mar 16, 2023 | Analysis, Funding, M&A, Partnership Deals
R&D Partnerships, M&A, Ventures, & IPOs in T.A. – Cancer The pharmaceutical industry continues to place significant emphasis on cancer treatment. A report by the International Agency for Cancer Research suggests that the number of deaths resulting from...
